Epitalon Dosage and Courses: What the Studies Used and What HHS Allows

No dose of epitalon is approved, and the doses in online dosing charts do not come from studies of epitalon. The published human work is three small regimens from one St. Petersburg research group, each given as a short course: 10 micrograms a day injected into muscle for 10 days in older adults, 5 micrograms per eye a day for 10 days by injection beside the eye in retinitis pigmentosa, and 0.5 mg a day as a spray under the tongue for 20 days in night-shift workers.^[3][2] Vendor charts list 5 to 10 mg a day, 500 to 1,000 times the injected daily dose reported in older adults.^[2][3] Since October 28, 2026, an interim HHS enforcement policy has covered 503A pharmacy compounding of epitalon acetate only as an injection under the skin or into muscle, “dispensed in intermittent courses.”^[1] The policy is not FDA approval, sets no dose and does not say how long a course is.

What the HHS policy says about epitalon courses

HHS’s interim policy covers six peptides, and epitalon is the only one with a limit on how it is dispensed as well as how it is given. The appendix says enforcement discretion for epitalon acetate “is appropriate subcutaneous or intramuscular injectable dosage forms that are dispensed in intermittent courses.”^[1] HHS gave three reasons for including it. The third reads:

“CDER’s safety concerns are mechanistic rather than based on observed harm, the limited controlled human exposure reported no side effects, and the documented regimens are intermittent rather than continuous.”^[1]

— HHS, Enforcement Discretion Policy, Appendix B (October 2026)

The concern HHS is answering comes from FDA’s own review. FDA’s reviewers worried that because epitalon switches on telomerase in cells, “continuous exposure to epitalon through the lifespan could enable cells to evade senescence and become cancerous.”^[2] HHS’s answer points to the regimens on record, which were all short courses, and the policy holds compounded epitalon to courses as well.

What the policy leaves out matters as much. It does not define a course, a gap between courses or a number of courses a year. It does not name the studies behind “limited controlled human exposure” or “documented regimens.” It sets no dose. Those choices fall to the prescriber who writes the patient-specific prescription the policy requires.^[1] The full list of conditions is in our guide to the HHS peptide policy.

The documented regimens: every course in the published record

The published research on epitalon comes almost entirely from Vladimir Khavinson’s St. Petersburg Institute of Bioregulation and Gerontology and its partners, and most of it is cell work. FDA’s 2026 review found three studies in which the peptide itself was given to humans, two of them in night-shift workers.^[2] A 2026 review led by physicians at Johns Hopkins read the full papers, recorded the doses, and noted that the two night-shift reports appear to describe overlapping groups.^[3] Together with the animal work, this is the whole set of epitalon regimens on record.

Every human course in the table lasted 10 or 20 days. The only long-term schedule, the mouse life-span study, gave the peptide five days a month, which FDA calculated added up to at most about 22 weeks of exposure over a mouse’s life.^[2] This is the record HHS describes as intermittent. None of the human studies used injection under the skin, the route proposed in the nominations to FDA, and FDA said it had found no human safety data for epitalon, “particularly via the proposed subcutaneous route.”^[2]

The longer schedules people quote come from a different product. Epithalamin, the cattle pineal-gland extract that epitalon was modeled on, was given in a 2006 study of older heart patients as five 10 mg injections into muscle, three days apart, every six months for three years.^[9][3] In monkeys the same group gave epithalamin at 5 mg per animal a day for 10 days.^[7] FDA treats epithalamin and epitalon as different substances.^[2]

Where the 5 to 10 mg a day in dosing charts comes from

When FDA surveyed clinic and vendor websites for its 2026 review, it found pages saying epitalon is injected under the skin or taken by mouth “with doses ranging from 5 mg to 10 mg per day,” some recommending cycles and one recommending it every four months.^[2] Vials were sold at 10, 20, 25 and 50 mg, alongside capsules and an oral spray.^[2] The nominations to FDA proposed injections at 10 mg and 3,000 micrograms per milliliter.^[2]

Set those numbers beside the studies and the gap is plain. The older-adult study injected 0.01 mg a day, so a 5 to 10 mg daily dose is 500 to 1,000 times larger. A single 10 mg vial holds 100 times the whole 10-day course in that study.^[3] The 5 to 10 mg range does match the doses used for epithalamin, the extract, in the Russian and Ukrainian studies.^[9][7] No published study links it to epitalon, and no study has compared doses of epitalon to find one that works or one that is safe.^[3]

Why these courses cannot be read as a protocol

A protocol is a dose someone has shown to be reasonably safe and effective for a stated use. The epitalon courses fall short of that on several counts.

• One group ran nearly all of it. The human studies, and almost all the animal work, come from Khavinson’s institute or close collaborators. No outside team has repeated a human study.^[2][3]
• Each study used one fixed dose. Of the monkey study, FDA noted that the authors “did not assess the dose-response relationship,” and no human study compared doses either. Without that, there is no way to say 10 micrograms is better or worse than 1 or 100.^[2][3]
• Nobody measured what happens to the drug. FDA found no pharmacokinetic data, so nobody knows how much epitalon reaches the blood after an injection or how long it stays there.^[2]
• The outcomes were lab markers. The older-adult and night-shift studies measured melatonin and gene activity. Neither used a validated sleep or disease outcome.^[2][3]
• The routes do not match what is sold. The human regimens used muscle, eye and under-the-tongue routes, and the 2026 review concluded that the mix of species, routes and schedules “prevents reliable determination of an optimal human dosing regimen.”^[3]
• The reporting is thin. The night-shift paper did not say whether it was blinded, and the eye study did not clearly describe randomization or blinding.^[2][3] The 2007 study is published in Russian, with an English abstract that gives no dose.^[5]

The same problem runs through the other HHS-policy peptides. For MOTS-c, no human dose exists at all (MOTS-c dosage and side effects). The peptide menu review compares how much human testing each one has had.

Epitalon nasal spray: outside the policy and barely studied

The HHS policy covers epitalon acetate only as an injection, under the skin or into muscle.^[1] A nasal spray is a different route, so a pharmacy that compounds one gets no protection from the policy. Semax is the only one of the six peptides the policy covers for intranasal use.^[1] A separate condition names an FDA 510(k)-cleared syringe as the only delivery device that may be packaged with or contain a compounded product; the policy does not say how that squares with a nasal product.^[1] Sellers of “research use only” sprays are outside the policy whatever the route; research-use-only vs compounded peptides explains the difference.

The evidence for a nasal route is one short rat study from the same network, which gave epitalon into the nose of stressed and unstressed rats and reported changes in the pineal gland only under stress. Its abstract gives no dose.^[10] The only human spray study used a sublingual spray, held under the tongue, made by a French supplier, at 0.5 mg a day for 20 days.^[2] Nobody has published a study of epitalon sprayed into the human nose. For the nasal peptide HHS did cover, see Semax vs Selank.

Epitalon side effects: what is documented and what is not

HHS wrote that the limited controlled human exposure “reported no side effects.”^[1] That matches the papers, but the papers were not built to find side effects.

Small, short studies that do not look for harms will rarely find them. The 2026 review put it directly: “the lack of reported adverse events should not be interpreted as evidence of safety.”^[3] The risks FDA raised are ones these studies could not have detected:

• Immune reactions. FDA said injected peptides can provoke antibodies, a risk that “may be enhanced when peptides are given via SC ROA,” with consequences ranging from no symptoms to severe reactions. Clumping of the peptide and impurities in the raw material add to the risk.^[2]
• Cancer, in theory. The telomerase effect that sellers market is the same one FDA flagged as a possible cancer risk with long exposure. No study has tested this in people, and the mouse work was too short to settle it.^[2]
• Product quality. The certificates of analysis FDA reviewed for epitalon lacked tests for endotoxins and microbes, which matter most in an injection. The HHS policy’s conditions include those tests.^[2][1] Our guide to reading a peptide certificate of analysis shows what to look for.

Side-effect lists on vendor and clinic pages do not come from published epitalon studies, because those studies reported none. Whatever their source, nobody has counted them.

If a prescriber offers epitalon

Under the policy, a compounded epitalon product must contain epitalon acetate alone, be made from tested raw material from an FDA-registered facility, carry the label “This is a compounded drug product. Not for resale,” and come with instructions for reporting problems.^[1] Ask the prescriber what course length and dose they are using and where those numbers came from, since neither HHS nor the studies supply them. Epitalon has no approved label and so no labeled blood tests; peptide blood work and monitoring covers what can and cannot be checked.

Under the policy’s conditions, the pharmacy reports serious adverse events to FDA.^[1] You or your prescriber can also report a problem directly through FDA MedWatch.^[11] Telehealth sellers that list epitalon are tracked on our epitalon provider page, and the epitalon peptide profile covers seller context. If you also take a GLP-1 or any other prescription, tell the prescriber about the epitalon.